Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza ...

Subscription revenue climbed 3% sequentially to Rs 1,050.2 crore in Q3 FY26 and rose 7% year-on-year, as stronger collections and higher other sales supported results.